U.S. market Closed. Opens in 17 hours 7 minutes

MLTX | MoonLake Immunotherapeutics Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-31
RevenueN/AN/AN/AN/A
Cost of Revenue13.16K12.36K4.97KN/A
Gross Profit-13.16K-12.36K-4.97KN/A
Operating Expenses54.11M65.06M53.57M105.75K
Selling, General & Admin22.32M23.01M18.05M105.75K
Research & Development31.79M42.05M35.52MN/A
Other Operating ExpensesN/A591.73KN/AN/A
Operating Income-54.12M-65.06M-53.58M-105.76K
Other Expenses / Income10.14M591.73K-61.85K14.92K
Before Tax Income-43.98M-64.47M-53.64M-90.84K
Income Tax Expenses94.39K36.37K4.75K-206.30K
Net Income-36.01M-64.51M-53.64M-90.84K
Interest ExpensesN/A-591.73KN/AN/A
Basic Shares Outstanding49.12M29.36M7.84M14.80M
Diluted Shares Outstanding49.12M29.36M7.84M14.80M
EBITDA-54.11M-65.06M-53.57M-105.76K
EBITDA Margin0.00%0.00%0.00%0.00%
EBIT-35.91M-65.06M-53.64M-297.13K
EBIT Margin0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙